A new review published in Frontiers argues that atopic dermatitis and psoriasis should be understood as dynamically evolving immune processes rather than fixed histopathological pictures — a framing the authors say better reflects how both diseases change across tissues, time and treatment.

The paper, titled "From static pathology to dynamic immunity: immunological plasticity and histopathological remodeling in atopic dermatitis and psoriasis," centers on two of the most prevalent chronic inflammatory skin diseases in dermatology. Its core proposition: the classical histopathological readouts clinicians rely on capture only a snapshot of disease, while the underlying immunology is continually remodeling.

Why does the static-versus-dynamic distinction matter?

Atopic dermatitis and psoriasis have long been defined by their hallmark histology — spongiotic eczematous change with eosinophilic and lymphocytic infiltrates in AD; acanthosis, parakeratosis and neutrophil-rich Munro microabscesses in psoriasis. The review's authors contend that these static descriptors understate the degree to which immune cell populations, cytokine networks and tissue architecture shift as lesions form, resolve and relapse.

Central to the analysis is the concept of immunological plasticity — the capacity of immune cells to adopt different functional states depending on microenvironmental cues. In inflammatory skin disease, that plasticity means the same cell type can drive distinct pathology in AD versus psoriasis, and can change its behavior within a single lesion over time.

How does histopathological remodeling fit in?

The second pillar of the review is histopathological remodeling: the structural changes in epidermis, dermis and vascular compartments that accompany — and feed back into — immune activation. The authors frame tissue remodeling and immune plasticity as coupled processes rather than parallel tracks.

This coupling has practical weight for a field increasingly organized around biologic therapy. Targeted agents such as IL-4/IL-13 and IL-17/IL-23 inhibitors were designed against cytokine axes defined by static snapshots of disease immunology. A dynamic model suggests treatment itself reshapes the immune and histological landscape, with implications for how clinicians interpret partial responses, relapse and sequential therapy.

What could change in clinical practice?

The review's perspective speaks most directly to how dermatologists conceptualize diagnosis and monitoring:

• Histology remains informative but is inherently time-locked; it describes where a lesion is, not where it is heading.
• Plastic immune populations may explain heterogeneous treatment responses within a single diagnosis.
• Remodeled tissue architecture can sustain inflammation even after upstream cytokine drivers are suppressed.
• Cross-disease comparison of AD and psoriasis may reveal shared plasticity mechanisms operating in opposite directions.

The choice to pair the two diseases in one analysis is deliberate. AD and psoriasis are often presented as immunological opposites — a Th2-skewed, type 2-driven eczema versus a Th17/Th23-driven papulosquamous disease. Placing them side by side lets the authors examine where that dichotomy holds and where plasticity blurs it.

For researchers, the review points toward longitudinal sampling and single-cell-level profiling as the tools needed to replace snapshot pathology with trajectory-based disease models. For clinicians, it reinforces the case that PASI and EASI scores, lesion appearance and biopsy findings each capture one frame of a moving process.

The authors' broader conclusion is that next-generation disease classification in inflammatory dermatoses should integrate immune-state dynamics with structural remodeling — an approach that could eventually inform how biologics are sequenced and how response is defined. Whether that conceptual shift translates into revised diagnostic criteria or monitoring standards will depend on the longitudinal studies the review calls for.